DOCSLIB.ORG

Kansas Eyecon 2015 Program Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kansas Eyecon 2015 Program Book 5 1 20 Kansas Kansas EyeCon EyeCon May 8 & 9, 2015 KU Edwards Campus BEST Conference Center 12604 Quivira Overland Park, KS 66213 Sponsored by the University of Kansas Department of Ophthalmology and the Lemoine Alumni Society Kansas EyeCon 2015 We wish to acknowledge and sincerely thank these organizations for exhibiting at this conference: Platinum Sponsors: Alcon Laboratories, Inc. Bausch + Lomb Ellex Glaukos Corporation Katena Instruments & Biologics Regeneron Pharmaceuticals, Inc. Silver Sponsors: Sightpath Medical Allergan, Inc. Bruce Biscanin Carl Zeiss Meditec, Inc. Heidelberg Engineering Quantel Medical NanoPac, Inc. Bronze Sponsor: KU Audio‐Reader Network Kansas EyeCon 2015 KU Edwards Campus, BEST Conference Center Overland Park, KS May 8 & 9, 2015 Program Overview: This conference is intended to provide ophthalmologists with an educational forum to learn about new developments in the profession and their application to patient care. Covering a cross-section of all sub-specialties, physicians can expect to walk away having heard evidence-based presentations. Target Audience: This program is designed to meet the needs of practicing ophthalmologists. Learning Objectives: Upon completion of the educational activity, participants should be able to: Neuro-Ophthalmology & Pediatrics Session 1. Identify changes in the diagnostic criteria for intracranial hypertension and apply recommended changes in treatment protocols for intracranial hypertension; 2. Review pediatric uveitis etiologies and common pediatric uveitis treatments; 3. Describe the standard systemic work-up for new-onset pediatric uveitis; 4. Review steroid-sparing agents for the treatment of pediatric uveitis. Anterior Segment & Orbito-Plastics Session 5. Describe the pathophysiology and mechanisms of intraocular pressure elevation in neovascular glaucoma; 6. Discuss the rationale for therapeutic approaches to neovascular glaucoma including the use of anti-VEGF agents; 7. Evaluate outcomes of trabeculectomy bleb needle revision with 5-fluorouracil; 8. Investigate relationship between outcomes and mechanism of glaucoma; 9. Outline the experimental model of pressure modulation in Baerveldt implants; 10. Discuss the clinical application of tubing inserts in Baerveldt implants for the reduction of post-operative hypotony; 11. Describe the presentation and differential diagnosis for osseous tumors commonly presenting with orbital involvement; 12. Discuss the medical and surgical management of osseous orbital tumors, including review of current literature; 13. Review orbital anatomy, orbital disease, and medical and surgical options; 14. Demonstrate a few simple maneuvers which may be helpful in avoiding/managing problems in routine cataract surgery, including surgicenter tips that may be helpful in efficiency and patient satisfaction. Retina Session 15. Review current recommendations for genetic testing for diagnostic of affected individuals and family members at risk to have affected offspring; 16. Review reported results and ongoing trials using gene therapy for inherited retinal disorders; 17. Evaluate the evidence regarding treatment of center involving macular edema with laser, VEGF inhibitors and steroids; 18. Evaluate the evidence for treatment of diabetic macular edema at the time of cataract surgery; 19. Correctly make a diagnosis when patients present with sub retinal fluid (SRF) in the elderly age group and management of these cases once a diagnosis is made; 20. Summarize photomechanical, photothermal and photochemical retinal injuries; 21. Analyze countermeasures against clinical and industrial photic injuries; 22. Determine if micropulse laser is effective in reducing macular edema and identify any relationships that promote better or worse outcomes; 23. Examine the effectiveness of dexamethasone intravitreal implant as adjunctive or sole treatment of persistent uveitis macular edema patients with Multiple Sclerosis. Cornea Session 24. Review historical techniques important to the development of current pterygium surgery; 25. Recognize newer techniques and materials used for pterygium surgery; 26. Describe the importance of properly done corneal cultures to help guide treatment in keratitis; 27. Discuss the relationship between diabetes mellitus and ocular surface disease, and diabetes mellitus and tear osmolarity; 28. Identify the mechanism of action by which Omega-3 free fatty acids will treat Dry Eye Disease; 29. Identify the principle endpoints of the clinical trial DREAM (Dry Eye Assessment and Management Study). Method of Participation: Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an activity evaluation/claimed credit form that should be turned it at the end of the meeting. If you have questions about this CME activity, please contact AKH Inc. at [email protected]. CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare Physicians This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the University of Kansas, Department of Ophthalmology and The Lemoine Alumni Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. FACULTY DISCLOSURES Name Relationship Commercial Interest Anna Berry, MD, MPH N/A Nothing to Disclose Miranda Bishara, MD N/A Nothing to Disclose Michelle Boyce, MD N/A Nothing to Disclose Emily Broxterman, MD N/A Nothing to Disclose Mary Champion, MD N/A Nothing to Disclose Alina V. Dumitrescu, MD N/A Nothing to Disclose Luther L. Fry, MD N/A Nothing to Disclose Derek Horkey, MD N/A Nothing to Disclose Martin A. Mainster, PhD, MD, FRCOphth. N/A Nothing to Disclose Paul Munden, MD N/A Nothing to Disclose Robert Null, MD N/A Nothing to Disclose Anjulie Quick, MD N/A Nothing to Disclose Matthew Recko, MD N/A Nothing to Disclose Ajay Singh, MD N/A Nothing to Disclose Jason Sokol, MD N/A Nothing to Disclose John Sutphin, MD N/A Nothing to Disclose R.C. Andrew Symons, MD, PhD N/A Nothing to Disclose W. Abraham White, MD N/A Nothing to Disclose Thomas J. Whittaker, MS, JD, MD N/A Nothing to Disclose Lillian Yang, MD N/A Nothing to Disclose PLANNER DISCLOSURES KUMC/KSEPS Staff and Planners N/A Nothing to Disclose AKH Staff and Planners N/A Nothing to Disclose Commercial Support: There is no commercial support for this activity. Disclosures: It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. Disclosure of Unlabeled Use and Investigational Product: This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. DISTINGUISHED LEMOINE ALUMNI LECTURERS LECTURER TITLE DATE Timothy W. Olsen, MD Rock Chalk Retina Talk: 100 year KU 5/9/2014 KU SOM MD ‘89 Luther L. Fry, MD Standard Cataract Surgery: Tips & Tricks 5/8/2015 KU SOM MD ‘67 Learned after 40,000+ Cases Alumni Speakers Luther L. Fry, MD MD: 1967 Thomas Whittaker, JD, MD, MS MD: 1990 AGENDA Kansas EyeCon May 8 – 9, 2015 KU Edwards Campus Friday, May 8, 2015 BEST Conference Center 12:00 p.m. Registration and lunch with exhibitors Neuro‐Ophthalmology & Pediatrics Section 1:00 p.m. Welcome: Miranda Bishara, MD 1:05 p.m. Thomas Whittaker, MD, 2015 Update on Pseudotumor Cerebri Syndrome 1:30 p.m. Matthew Recko, MD, Pediatric Uveitis 1:55 p.m. Anna Berry, MD, Efficacy
Load more

Recommended publications
  • Meeting Materials
    BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY EDMUND G. BROWN JR., GOVERNOR STATE BOARD OF OPTOMETRY 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834 0 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov OPToMi fikY Continuing Education Course Approval Checklist Title: Provider Name: ☐Completed Application Open to all Optometrists? ☐ Yes ☐No Maintain Record Agreement? ☐ Yes ☐No ☐Correct Application Fee ☐Detailed Course Summary ☐Detailed Course Outline ☐PowerPoint and/or other Presentation Materials ☐Advertising (optional) ☐CV for EACH Course Instructor ☐License Verification for Each Course Instructor Disciplinary History? ☐Yes ☐No BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY GOVERNOR EDMUND G. BROWN JR. ~~ TATE BOARD OF OPTOMETRY }I /~E{:fLi\1 ~1' DELWSO ROAD, SUITE 105, SACRAMENTO, CA 95834 op'i,otii~l~ 1~0-A~ifiF' t\,rffi-7170 F (916) 575-7292 www.optometry.ca.gov EDUCATION COU Rw1t;--ftf""~'-!-J/-i~--,--__:___::...:..::....::~-~ $50 Mandatory Fee APPLICATION ,-~Jg l Pursuant to California Code of Regulations (CCR) § 1536, the Board will app~romv~e~c~ott=nfli1~nuFTT1t;tngn'zeWl:uc~rRif'tf-:~MT~~=ilt,;;,,_J receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g). In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date. Please type or print
    [Show full text]
  • National Eye Institute Visual Function Questionnaire (NEI- VFQ25) in Subjects with IIH and Normal Controls
    Title: Correlation of Visual Function and National Eye Institute Visual Function Questionnaire (NEI- VFQ25) in subjects with IIH and normal controls. Melanie Truong, DO OD Introduction and Purpose Aims of the study: 1. To assess contrast sensitivity acuity and rapid eye movements (saccades) as a measure of visual function in Idiopathic Intracranial Hypertension (IIH) patients compared to normal patients using the King-Devick Variable Contrast Acuity Chart and the K-D rapid eye movement. 2. To assess subjects quality of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ25) questionnaire and Supplement as a comparison between IIH subjects and normal controls. 3. To study the correlation between visual function and quality of visual function questionnaire in subjects with IIH compared to normal controls. Contrast sensitivity is a measure of afferent visual system. Contrast sensitivity deficit with preservation of normal Snellen acuity has also been reported in glaucoma, compressive disorders of the anterior visual pathways, retinal diseases, and with cerebral lesions.1 This test is significantly more sensitive than Snellen acuity .1 It is also superior for serial testing in patients as there was significant improvement in contrast scores and papilledema grade but no significant change in Snellen acuity.1 Visual manifestation of IIH can also include parafoveal deficits. This can lead to deficits in spatial frequency contrast sensitivity.1 Contrast sensitivity is abnormal initially and improved with regression of papilledema.2 Since decisions on therapy in IIH are based on the presence and change in visual function, assessing visual acuities is not the most accurate measure of visual status in IIH.
    [Show full text]
  • Central Serous Papillopathy by Optic Nerve Head Drusen
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article CASE REPORT Central serous papillopathy by optic nerve head drusen Ana Marina Suelves1 Abstract: We report a 38-year-old man with a complaint of blurred vision in his right eye for the Ester Francés-Muñoz1 previous 5 days. He had bilateral optic disc drusen. Fluorescein angiography revealed multiple Roberto Gallego-Pinazo1 hyperfluorescent foci within temporal optic discs and temporal inferior arcade in late phase. Diamar Pardo-Lopez1 Optical coherence tomography showed bilateral peripapillary serous detachment as well as right Jose Luis Mullor2 macular detachment. This is the first reported case of a concurrent peripapillary and macular Jose Fernando Arevalo3 detachment in a patient with central serous papillopathy by optic disc drusen. Central serous papillopathy is an atypical form of central serous chorioretinopathy that should be considered Manuel Díaz-Llopis1,4,5 as a potential cause of acute loss of vision in patients with optic nerve head drusen. 1 Department of Ophthalmology, La Fe Keywords: central serous papillopathy, peripapillary central serous chorioretinopathy, optic University Hospital, Valencia, Spain; For personal use only. 2Instituto de Investigación Sanitaria, nerve head drusen, peripapillary subretinal fluid Fundación para la investigación, La Fe Hospital, Valencia, Spain; 3Retina and vitreous service, Clínica Introduction Oftalmológica Centro Caracas, Optic nerve head drusen (ONHD) are hyaline material calcificated
    [Show full text]
  • Idiopathic Intracranial Hypertension
    IDIOPATHIC INTRACRANIAL HYPERTENSION William L Hills, MD Neuro-ophthalmology Oregon Neurology Associates Affiliated Assistant Professor Ophthalmology and Neurology Casey Eye Institute, OHSU No disclosures CASE - 19 YO WOMAN WITH HEADACHES X 3 MONTHS Headaches frontal PMHx: obesity Worse lying down Meds: takes ibuprofen for headaches Wake from sleep Pulsatile tinnitus x 1 month. Vision blacks out transiently when she bends over or sits down EXAMINATION Vision: 20/20 R eye, 20/25 L eye. Neuro: PERRL, no APD, EOMI, VF full to confrontation. Dilated fundoscopic exam: 360 degree blurring of disc margins in both eyes, absent SVP. Formal visual field testing: Enlargement of the blind spot, generalized constriction both eyes. MRI brain: Lumbar puncture: Posterior flattening of Opening pressure 39 the globes cm H20 Empty sella Normal CSF studies otherwise normal Headache improved after LP IDIOPATHIC INTRACRANIAL HYPERTENSION SYNDROME: Increased intracranial pressure without ventriculomegaly or mass lesion Normal CSF composition NOMENCLATURE Idiopathic intracranial hypertension (IIH) Benign intracranial hypertension Pseudotumor cerebri Intracranial hypertension secondary to… DIAGNOSTIC CRITERIA Original criteria have been updated to reflect new imaging modalities: 1492 Friedman and Jacobsen. Neurology 2002; 59: Symptoms and signs reflect only those of - increased ICP or papilledema 1495 Documented increased ICP during LP in lateral decubitus position Normal CSF composition No evidence of mass, hydrocephalus, structural
    [Show full text]
  • Amaurosis Fugax (Transient Monocular Or Binocular Vision Loss)
    Amaurosis fugax (transient monocular or binocular vision loss) Syndee Givre, MD, PhD Gregory P Van Stavern, MD The next version of UpToDate (15.3) will be released in October 2007. INTRODUCTION AND DEFINITIONS — Amaurosis fugax (from the Greek "amaurosis," meaning dark, and the Latin "fugax," meaning fleeting) refers to a transient loss of vision in one or both eyes. Varied use of common terminology may cause some confusion when reading the literature. Some suggest that "amaurosis fugax" implies a vascular cause for the visual loss, but the term continues to be used when describing visual loss from any origin and involving one or both eyes. The term "transient monocular blindness" is also often used but is not ideal, since most patients do not experience complete loss of vision with the episode. "Transient monocular visual loss" (TMVL) and "transient binocular visual loss" (TBVL) are preferred to describe abrupt and temporary loss of vision in one or both eyes, since they carry no connotation regarding etiology. Transient visual loss, either monocular or binocular, reflects a heterogeneous group of disorders, some relatively benign and others with grave neurologic or ophthalmologic implications. The task of the clinician is to use the history and examination to localize the problem to a region in the visual pathways, identify potential etiologies, and, when indicated, perform a focused battery of laboratory tests to confirm or exclude certain causes. Therapeutic interventions and prognostic implications are specific to the underlying cause. This topic discusses transient visual loss. Other ocular and cerebral ischemic syndromes are discussed separately. APPROACH TO TRANSIENT VISUAL LOSS — By definition, patients with transient visual loss almost always present after the episode has resolved; hence, the neurologic and ophthalmologic examination is usually normal.
    [Show full text]
  • Polycythemia Vera Presenting with Bilateral Papilledema Retinitis
    July - August 2009 Lett ers to the Editor 325 Amjad Salman, Pragya Parmar, vary signiÞ cantly. With the increasing use of MRI in all cases Vanila G Coimbatore, Rajmohan Meenakshisunderam, suspected to be a brain syndrome, CVT has been increasing Nelson Jesudasan A Christdas diagnosed. MRI is now the gold standard in the diagnosis of CVT as rightly done in this case. Institute of Ophthalmology, Joseph Eye Hospital, Tiruchirapalli - 620 001, India Visual loss in CVT maybe due to thrombotic ischemia of any structure of the visual pathway or due to pressure on the optic Correspondence to Dr. Salman Amjad, Institute of Ophthalmology, Joseph Eye Hospital, Tiruchirapalli - 620 001, India. nerve due to the transmitt ed raised intracranial pressure (ICP). E-mail: [email protected] All cases of CVT with visual loss require visual Þ eld analysis and measurement of optic nerve sheath diameter using B-scan References ultrasonography (USG). Visual loss in patients with CVT due to transmitt ed raised ICP (indicated by increased optic nerve sheath 1. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. diameter on USG) not amenable to medical management is an Safety of an intravitreal injection of triamcinolone: Results from a indication for optic nerve sheath decompression (ONSD). ONSD randomized clinical trial. Arch Ophthalmol 2004;122:336-40. as a treatment option for the visual loss in the left eye should have 2. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone acetonide for macular edema. Am J been off ered to the patient in this case, as it has been shown to [4,5] Ophthalmol 2006;141:629-37.
    [Show full text]
  • Papilledema": Neuroradiologic Evaluation of Optic Disk Protrusion with Dynamic Orbital CT
    681 "Papilledema": Neuroradiologic Evaluation of Optic Disk Protrusion with Dynamic Orbital CT John R. Jinkins 1 Current-generation CT scc·lners enable the visualization in vivo of structures and substructures that were previously unobservable. Certainly the orbit and optic nerve/ sheath complex have demonstrated a great number of pathologic and normal anatomic variations. It has been found in patients with elevated intracranial pressure that what was previously thought to be simple papilledema in fact masks a surprisingly large component of optic papilla protru<;ion, There may be a variable amount of increased intercellular/axonal fluid within tt.. - optic disk in patients with increased intracranial pressure; however, a significant factor in the " swollen disk" is the simple transmission of pressure along the optic nerve sheath to the papilla, causing it to bulge. Further investigations with dynamic CT reveal that there is decreased perfusion of the optic disk in the active phase of severe increased intracranial pressure in patients with papilledema and/or protrusion as compared with normal control subjects. This de­ pressed flow pattern seems to originate subacutely and appears to resolve in certain patients after normalization of the elevated pressure. These findings apparently indicate that clinical intervention in cases of intracranial hypertension to restore the hemodynamic status of the optic disk would be timely, and thereby avert irreversible damage. This suggests and supports the theory that increased intracranial pressure may lead to rapid vision loss by the mechanical mechanism of pressure projected directly to the junction of the optic nerve and optic nerve head, leading to decreased perfusion, ischemia, axonal flow stasis, and resultant optic nerve atrophy.
    [Show full text]
  • Pseudotumor Cerebri and Papilledema an OVERVIEW of THIS PERPLEXING SYNDROME and ITS HALLMARK PRESENTATION
    Pseudotumor Cerebri and Papilledema AN OVERVIEW OF THIS PERPLEXING SYNDROME AND ITS HALLMARK PRESENTATION. BY RUI WANG; ASHWINI KINI, MD; BAYAN AL OTHMAN, MD; AND ANDREW G. LEE, MD seudotumor cerebri, also IIH and secondary intracranial hyper- specific, headaches associated with IIH known as idiopathic intra- tension due to cerebral venous throm- are often daily and are retroocular.9 Pcranial hypertension (IIH), bosis and other causes of obstructed The headaches may resemble migraine describes the perplexing syndrome of venous outflow. headaches with associated symptoms increased intracranial pressure (ICP) Additionally, several systemic dis- of nausea, vomiting, and photophobia. in the absence of a space-occupying eases, drugs, and vitamin deficiencies In fact, many patients with IIH have lesion on neuroimaging or other or excesses have been reported to be coexisting migraine headaches, mak- etiology. Although the disease can associated with IIH. Of medications ing the diagnosis difficult.10 be observed in patients of any age, associated with IIH, growth hormones, Transient visual obscurations IIH classically presents among obese tetracyclines, and retinoids have been (TVOs) have been found to occur (body mass index >30) women of the most often reported.3-5 Other in about two-thirds of patients with childbearing age. Due to the increased systemic illnesses associated with papilledema. TVOs typically last only prevalence of obesity in recent years, pseudotumor cerebri include Addison seconds at a time and may be bilater- a significant
    [Show full text]
  • Central Retinal Vein Occlusion  Amaurosis Fugax  Acute-Angle Closure  Retinal Detachment Glaucoma  Vitreous Hemorrhage Problem with Ophthalmology
    Top Eye Emergencies Jason Knight, MD Medical Director of Emergency Services Houston Methodist Health System Houston, TX I am going to let you in on a little secret I was terrible at ophthalmology in medical school and residency “Fake it and hopefully you will make it” Maid of Honor in my wedding was an ophthalmologist so she kept me out of trouble I always prayed that I did not get “Eye” cases Once I became faculty – that didn’t work anymore Studied, read, asked questions, spent some time with ophthalmology residents: Two transformations occurred Made a series of eye lectures “I didn’t get it” so I decided to teach it a different way ED Physician Ophthalmology Fears “The patient is going to lose their vision and it is going to be my fault” “I am going to miss something major and not recognize it “I don’t know where to start with EYE patients” “I have no idea what I am looking at…but I am glad it’s not my eye” “I can’t get a good view or image” “Will I cause damage to the eye if I do a physical exam?” “Do I need to wake up ophthalmology at 0300 to come in and see this?” “Blurry Vision” Eye Disorders Keratitis Corneal Ulcers Scleritis Central Retinal Artery Uveitis/Iritis Occlusion Optic Neuritis Central Retinal Vein Occlusion Amaurosis Fugax Acute-Angle Closure Retinal Detachment Glaucoma Vitreous Hemorrhage Problem with Ophthalmology 12 Case 1: Do you give out your cell phone number to patients/ED Staff? 1. Yes – Almost always 2.
    [Show full text]
  • Orbital Cellulitis
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1933 Orbital cellulitis Warren McClatchey University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Recommended Citation McClatchey, Warren, "Orbital cellulitis" (1933). MD Theses. 277. https://digitalcommons.unmc.edu/mdtheses/277 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. ORBITAL CELLULITIS SENIOR Th'"ESIS ORBITAL CELLULI~IS BY Warren McClatchey 1933 I 0R!2.I1:~k-CE~LU~ITIS Introduc·tion The diseas6 known as orbital cell~lltis 1s a purulent inflamation of the cellular tissues of the orbit. The subject is .:)f interest from a diagnostic stand point since it might ue confused with intercranlal condltions. It is also of interest beoause of the relationship it bears to diseases of the nose and acessory sinuses. A good history of the s;J.bject has not yet been written. Anderson Or i tcnet t reported a case to the Ophthalmological Society of the United Kingdom in 1886. (1). The case aad been diagn:)sed as a-horde:)lum. Later thE:Jre occured proJtosis of the rl",ht eye with frontal and orbital pain. The vision was reduced and the reaction to light slug;;:lsh. The temperature 0 was 100 F.
    [Show full text]
  • Periorbital Swelling: the Important Distinction Between Allergy and Infection P W a Goodyear, a L Firth, D R Strachan, M Dudley
    240 Emerg Med J: first published as 10.1136/emj.2002.004721 on 26 February 2004. Downloaded from CASE REPORTS Periorbital swelling: the important distinction between allergy and infection P W A Goodyear, A L Firth, D R Strachan, M Dudley ............................................................................................................................... Emerg Med J 2004;21:240–242. doi: 10.1136/emj.2002.004051 DISCUSSION Orbital cellulitis and abscess formation are rare complica- Orbital cellulitis is an emergency. It is important that it is tions of sinusitis, however acute orbital inflammation is recognised early and managed aggressively. Although the secondary to sinusitis in about 70% of cases. Delay in incidence of orbital cellulitis has remained low with better diagnosis must not occur to avoid serious complications such primary health care and availability of a broad range of as blindness and life threatening intracranial sepsis. A case is antibiotics, it is often a difficult problem to manage and may reported in which despite late referral, emergency surgical cause blindness if left untreated because of optic nerve intervention was sight saving. compression. Both orbital abscess and cavernous venous thrombosis may lead to intracranial spread of infection, such as meningitis or cerebral abscess with high morbidity and possible mortality. 14 year old boy presented to the accident and The serious risk of complications in such cases was made emergency department of a district general hospital clear by Hodges et al1 who studied the outcome in orbital Awith a 24 hour history of a painful swollen left eye, cellulitis in a developing country. They found a high rate of exacerbated by movement. A history of allergy to dog hair complications, 52% blind on admission, with no improve- was noted.
    [Show full text]
  • Acute Central Serous Chorioretinopathy — an Uncommon Complication of Imatinib Mesylate (Imatinib) Therapy in Chronic Myelogenous Leukaemia
    CaSe report DoI: 10.5603/oJ.2020.0003 Acute central serous chorioretinopathy — an uncommon complication of imatinib mesylate (imatinib) therapy in chronic myelogenous leukaemia sanjay Kumar Mishra, ashok Kumar Department of Ophthalmology, Army College of Medical Sciences and Base Hospital, Delhi, India aBstraCt Imatinib is the most widely used drug in targeted therapy for chronic myelogenous leukaemia (CML). Few ophthal- mic side effects like periorbital oedema, epiphora, ptosis, extraocular muscle palsy, blepharoconjunctivitis, glaucoma, papilledema, photosensitivity, retinal haemorrhage, and increased intraocular pressure are described with imatinib therapy. A 35-year-old male, a known case of CML with no ocular complaints, on treatment with imatinib for the preceding six weeks, presented with acute central serous chorioretinopathy in the left eye. Owing to his professional requirements for early visual recovery, he was treated with subthreshold micropulse laser with complete resolution of the subretinal fluid. This case report highlights acute central serous chorioretinopathy as a potential rare complication of imatinib therapy in CML patients, which requires regular and detailed ophthalmic evaluation so as to diagnose and treat it without any residual effects. Key words: imatinib mesylate (imatinib); chronic myelogenous leukaemia (CML); central serous chorioretino- pathy Ophthalmol J 2020; Vol. 5, 8–11 introduCtion ocular presentations that includes retinal and iris Chronic myelogenous leukaemia (CML) is neovascularisation, haemorrhages, glaucoma, vitre- a clonal stem cell disorder of haemopoietic stem ous haemorrhages, Roth spots, nerve fibre infarcts, cells. It occurs due to reciprocal translocation be- and papilledema [3, 4]. tween chromosomes 9 and 22, t (9; 22), which Imatinib treatment can also lead to certain oph- results in a fusion gene product BCR-ABL on chro- thalmic side effects like periorbital oedema, epipho- mosome 22.
    [Show full text]